http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2068938-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
filingDate | 2007-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d4ffd2372054edc7de699de2f630d8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a5fd08afa0683c122712506440896f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8a0f5e9e32b3fb801eec5afc6dfba7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_652f6b904b8c7862caa5c69013ab951a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe952237794d2a730d9ecb0a44d114c3 |
publicationDate | 2011-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2068938-B1 |
titleOfInvention | Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib |
abstract | The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed amount of a Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a Ph+ leukemia in a manner that a Cmin is achieved in each single patient equal to or higher than the Cmin threshold obtained under step (d). |
priorityDate | 2006-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 305.